A New Protein Enabling Cancer to Evade the Immune System Has Been Discovered

The 10 fundamental characteristics of cancer cellsinclude learning, in relation to the immune system , to become invisible . Immune checkpoint proteinswere discovered, leading to the development of new-generation immunotherapies that revolutionized cancer treatment. In July 2019, Nature published a study identifying a protein that enables cancer cells to become invisible to immune system cells, CD24 . This development may pave the way for effective treatments against ovarian (female ovary) and breast cancer.
Macrophages, are immune system cells capable of identifying and destroying cancer cells. However, cancer cells have developed strategies to hide from macrophages . One of these strategies is for cancer cells to use proteins found in normal cells against the immune system. Two such signaling proteins, PD-1 and CTLA-4 were discovered previously. These discoveries enabled development of immune checkpoint inhibitors, which revolutionized cancer treatment. Last year, the two scientists who discovered these proteins won the Nobel Prize in Medicine. Previous studies showed that PD-L1, CD47 and Beta-2 microglobulin proteins are used by cancer cells against the immune system. Antibodies blocking CD47 are currently being tested in clinical studies. Drugs targeting the PD-L1 or PD-1 receptor are actively used to treat various cancers.
In clinical studies some cancer patients were found not to respond to anti-CD47 antibody therapy. Researchers investigated whether patients who did not respond had alternative signaling pathways . They first examined proteins produced in large amounts in cancer cells.
According to the analysis results;
- the CD24 proteinwas found in greater amounts in cancer cells.
- Macrophage cells reaching the tumor site were observed to receive the CD24 signal through a SIGLEC-10 receptor (see the figure below). In this way, macrophages see cancer cells as friends . Analyses using human macrophage cells and cancer cells showed that, after the CD24 signaling pathway was blocked with antibodies developed in the laboratory, macrophages attacked the cancer cells.
- In mouse models of breast cancer, macrophages were observed to attack cancer cells effectively when the CD24 signaling pathway was blocked.
- At the same time, the CD24 signaling pathway was found to work together with the CD47 signaling pathway. Ovarian and breast cancers were found to be more sensitive to anti-CD27 antibodies.

So what does this study mean for us?
- The second main signaling pathway enabling cancer cells to become invisible to the immune system has been discovered. The discovery of CD27 and CD24 proteins may pave the way for effective new-generation cancer treatments.
- It must be emphasized that this study is still at the preclinical drug development stage. Further analyses and clinical studies are required.
- Effective immunotherapies may be developed particularly against breast and ovarian cancer.
Sources
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Nature, 31 July 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.